Schonfeld Strategic Advisors LLC Gracell Biotechnologies Inc. Transaction History

Schonfeld Strategic Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$2.83 - $4.9 $610,447 - $1.06 Million	215,706 Added 39.67%	759,393 $2.19 Million
Q2 2023 Aug 14, 2023	SELL	$1.45 - $6.07 $100,763 - $421,816	-69,492 Reduced 11.33%	543,687 $2.07 Million
Q1 2023 May 15, 2023	BUY	$1.8 - $2.5 $429,008 - $595,845	238,338 Added 63.58%	613,179 $1.14 Million
Q4 2022 Feb 14, 2023	BUY	$2.08 - $3.96 $217,709 - $414,485	104,668 Added 38.74%	374,841 $862,000
Q3 2022 Nov 14, 2022	BUY	$2.08 - $5.15 $25,477 - $63,082	12,249 Added 4.75%	270,173 $870,000
Q2 2022 Aug 15, 2022	BUY	$1.95 - $5.5 $502,951 - $1.42 Million	257,924 New	257,924 $1.42 Million
Q3 2021 Nov 16, 2021	SELL	$9.91 - $14.84 $370,762 - $555,208	-37,413 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$9.75 - $18.42 $155,025 - $292,878	-15,900 Reduced 29.82%	37,413 $486,000
Q1 2021 May 17, 2021	BUY	$14.7 - $30.57 $783,701 - $1.63 Million	53,313 New	53,313 $822,000

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.